Market capitalization | $6.82m |
Enterprise Value | $-1.47m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.10 |
P/B ratio (TTM) P/B ratio | 0.20 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-11.07m |
Free Cash Flow (TTM) Free Cash Flow | $-14.09m |
Cash position | $8.52m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
1 Analyst has issued a forecast Purple Biotech Ltd - ADR:
1 Analyst has issued a forecast Purple Biotech Ltd - ADR:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.19 -0.19 |
5%
5%
|
|
EBITDA | -11 -11 |
51%
51%
|
EBIT (Operating Income) EBIT | -11 -11 |
50%
50%
|
Net Profit | -7.24 -7.24 |
64%
64%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Tel Aviv, Israel.
Head office | Israel |
CEO | Gil Efron |
Employees | 9 |
Founded | 1968 |
Website | www.purple-biotech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.